A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
PMV Pharmaceuticals, Inc
Mayo Clinic
Tizona Therapeutics, Inc
Essen Biotech
Eli Lilly and Company
Novartis
Compugen Ltd
Inspirna, Inc.
NextCure, Inc.
Celldex Therapeutics
Corvus Pharmaceuticals, Inc.
Kineta Inc.
M.D. Anderson Cancer Center
Incyte Corporation
Incyte Corporation